President’s Letter | July 2021 From the Desk of Samantha Guild I was struck several times this month with the idea that the fight against…
FDA Orphan Drug Designation Granted to Melanoma Drug Alrizomadlin July 21, 2021 (repost) Sara Karlovitch The FDA has granted an orphan drug designation to alrizomadlin, an MDM2-p53 inhibitor, for…
Chad Freitas and the Skiff Sailing Foundation By Alicia Rowell, Vice President It was 1986. Chad Freitas was six years old, and he and his dad drove…
The Psychological Well-Being of Skin Cancer Patients By Alicia Rowell, Vice President With a mom who is a professor of Research Methods in Applied Psychology at the…
International Survivor Spotlight: Hedva Gonen, Israel By Mara Klecker Hedva Gonen received her diagnosis via email while sitting alone in her home in Haifa, Israel. As…
Gut Microbes Signal Response to Immune Therapy in Melanoma (re-post from original article in GEN News) Programmed cell death protein 1 (PD-1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) are…
EORTC and Pierre Fabre Partner to Address Treatment Gap for Stage II Melanoma Patients Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage II melanoma patients EUROPEAN ORGANISATION…
Istari Oncology Announces FDA Granted Fast Track Designation to PVSRIPO for the Treatment of Advanced Melanoma June 14, 2021 08:03 AM Eastern Daylight Time | Source: Business Wire DURHAM, N.C.–(BUSINESS WIRE)–Istari Oncology, Inc., a clinical-stage biotechnology…
I’ve Been Diagnosed With Skin Cancer. Now What? You receive a phone call from your doctor that your biopsy results are back—it’s skin cancer. Now what? First of…
Alkermes’s disappointment hones melanoma niche focus June 04, 2021 | Source: Madeleine Armstrong, Evaluate Vantage Alkermes plays up responses in mucosal melanoma, but those hoping for…